|2.||Nephrotic Syndrome (Syndrome, Nephrotic)
|4.||IGA Glomerulonephritis (IGA Nephropathy)
|5.||Systemic Lupus Erythematosus (Libman-Sacks Disease)
|1.||Pusey, Charles D: 47 articles (09/2015 - 02/2002)|
|2.||Kitching, A Richard: 45 articles (12/2015 - 02/2002)|
|3.||Holdsworth, Stephen R: 44 articles (12/2015 - 02/2002)|
|4.||Cook, H Terence: 43 articles (09/2015 - 02/2002)|
|5.||Sethi, Sanjeev: 26 articles (01/2016 - 08/2003)|
|6.||Kawachi, Hiroshi: 26 articles (01/2015 - 04/2002)|
|7.||Fervenza, Fernando C: 23 articles (01/2016 - 05/2004)|
|8.||Floege, Jürgen: 23 articles (07/2015 - 03/2002)|
|9.||Falk, Ronald J: 23 articles (05/2015 - 10/2002)|
|10.||Anders, Hans-Joachim: 22 articles (11/2015 - 02/2003)|
|1.||Antineutrophil Cytoplasmic Antibodies (ANCA)IBA
01/01/2011 - "High-dose steroid therapy is very effective for ANCA-related glomerulonephritis. "
08/01/2009 - "On pathological evaluation, activity scores, chronicity indexes, relapse rates, and the frequency of positive serum anti-neutrophil cytoplasmic antibody (ANCA) were each significantly higher, whereas complete remission rates and renal outcomes, over a mean follow-up of 4 years, were significantly poorer in patients with crescentic glomerulonephritis. "
01/01/2007 - "When judging relapse and remission in ANCA-associated glomerulonephritis, it is important to evaluate the overall clinical findings and histopathological findings in addition to the serial ANCA titers."
05/01/2000 - "The next millennium will be marked by improved prognosis for ANCA-negative glomerulonephritis compared with that observed with this devastating disease in past decades."
04/01/2015 - "Future studies will try to determine if and how renal histology could be helpful in guiding treatment of ANCA-associated glomerulonephritis. "
|2.||Antigen-Antibody Complex (Immune Complex)IBA
10/01/2005 - "Perhaps the best treatment for glomerulonephritis is the identification and correction of any underlying inflammatory, immune-mediated or neoplastic disease that results in the deposition or formation of glomerular immune complexes. "
01/01/1996 - "Glomerular structural damage expressed as glomerular damage index was significantly greater in rats with immune complex glomerulonephritis when compared with controls (immune complex glomerulonephritis 0.91 +/- 0.13; control 0.60 +/- 0.08; P < 0.05), but was uneffected by the treatment with the CEI (immune complex) glomerulonephritis + CEI 1.02 +/- 0.26; control + CEI 0.63 +/- 0.11). "
11/22/2003 - "Assuming that a decrease in CD2AP attenuates clearance of glomerular immune complexes, patients with other types of idiopathic glomerulonephritis should also have a CD2AP mutation. "
07/01/1982 - "Impairment of glomerular clearance of macroaggregates in immune complex glomerulonephritis."
08/01/2015 - "In conclusion, the results of the present study suggested that the activation of NF-κB and upregulation of UCH-L1 in podocytes may be vital in podocyte injury associated with immune complex-mediated glomerulonephritis."
|3.||Cyclophosphamide (Cytoxan)FDA LinkGeneric
08/01/2001 - "Cyclophosphamide (CYC) has proven beneficial in preserving renal function in patients with lupus with diffuse proliferative glomerulonephritis (DPGN). "
03/01/2012 - "Our results show that pulse cyclophosphamide is an effective regimen for induction therapy in children with diffuse proliferative glomerulonephritis. "
09/01/1999 - "All patients had severe generalized disease with pauci-immune necrotizing glomerulonephritis and received standard induction therapy with oral cyclophosphamide and OCS for a mean of 14 wk until remission was achieved. "
08/01/1998 - "We report two patients with diffuse proliferative glomerulonephritis who responded favorably to MMF therapy after i.v. cyclophosphamide failed."
11/01/1991 - "A few months later she developed glomerulonephritis and responded well to cyclophosphamide treatment. "
|4.||Immunoglobulin G (IgG)IBA
04/01/1999 - "A total of 100 microg of pCAGGSIL-12 improved the Th1/Th2 balance in vivo, suppressed the production of IgG, and significantly reduced the development of glomerulonephritis. "
01/01/2009 - "Polyclonal immunoglobulin G ameliorates the course of progressive mesangioproliferative glomerulonephritis in rats."
03/01/1985 - "Mature female NZB/W mice (aged 5-7 months) with early glomerulonephritis showed no differences in MPS clearance of A-IgG compared with younger NZB/W mice without glomerulonephritis. "
01/01/1985 - "The function of the mononuclear phagocyte system was assessed in vivo in 85 patients with primary and secondary glomerulonephritis, by measuring the clearance of IgG - sensitised 51Cr-labelled autologous erythrocytes. "
05/01/1984 - "In the mesangio-capillary glomerulonephritis patients, the clearance rates of the IgG cells were fast-normal in six and enhanced in two, and correlated with the clearance of HDE. "
03/01/1991 - "For individual patients, as SC5b-9 concentration returned to normal there was a coincident decrease in serum creatinine concentration and urinary protein excretion, signifying clinical improvement in glomerulonephritis. "
09/01/2014 - "The serum creatinine levels were significantly higher in patients with immune-mediated glomerulonephritis with than in those without occult HCV (1.5 versus 1.1 mg/dl, respectively). "
04/01/2013 - "The renal function did not recover in children with creatinine clearance rate of less than 30 ml/(min·1.73 m(2)), who showed crescentic glomerulonephritis or sclerotic glomerulonephritis. "
10/01/2011 - "TLR3 expression correlated positively with HCV viral load, interleukin-1β, serum creatinine and inversely with creatinine clearance in patients with HCV-positive glomerulonephritis. "
04/01/2011 - "A total of 189 (113 males and 76 females) patients with idiopathic glomerulonephritis and serum creatinine of less than 150 μmol/L diagnosed between 1993 and 2004 were followed up to their last visit in 2009. "
08/15/2012 - "Our data also reveal that the BALB/c background is protective against autoimmune-mediated glomerulonephritis, even in the face of high titer autoantibodies, whereas the C57BL/6 background is susceptible. "
12/01/2004 - "In contrast, a significant delay in the development of autoantibodies and glomerulonephritis was observed in C1qa(-/-) mice reconstituted with wild-type BMC, and the impaired clearance of apoptotic cells, previously described in C1qa(-/-) mice, was rectified. "
01/01/2015 - "BXD2 mice spontaneously develop autoantibodies and subsequent glomerulonephritis, offering a useful animal model to study autoimmune lupus. "
01/15/1992 - "Moreover, investigation of these autoantibodies will be of immense value in future studies focused on the pathogenic mechanisms involved in glomerulonephritis."
01/01/2015 - "The clinical improvements in Ibrutinib-treated recipients were associated with decreased serum-autoantibodies, costimulatory molecule activation, B-cell proliferation, and glomerulonephritis compared to vehicle controls. "
07/01/1997 - "These results suggest that methylprednisolone pulse therapy may be very effective for the insidious type of crescentic glomerulonephritis."
01/01/2010 - "These findings indicate that methylprednisolone pulse therapy is effective in patients with chronic glomerulonephritis and has an acceptably low risk of side effects."
06/01/1992 - "In an attempt to clarify the indication and efficacy of the methylprednisolone pulse therapy (1000 mg x 3 times) for rapidly progressive glomerulonephritis (RPGN), 3 patients with the disease were carefully followed and the clinical course during and after the treatment were precisely analysed. "
01/01/2015 - "It is worth paying more attention to patients with rapidly progressive glomerulonephritis (RPGN), as they might be complicated with RPLS during intravenous administration of CTX and methylprednisolone. "
11/01/2014 - "With active bullous SLE with rapidly progressive glomerulonephritis suspected, she was treated with methylprednisolone pulses without response. "
|8.||antiglomerular basement membrane antibodyIBA
09/15/2009 - "This novel attenuated model allows elucidating the relative contribution of different mediator systems of the immune system to the development of renal injury, and also provides a platform for the assessment of different treatment protocols and evaluation of drugs that ultimately may be beneficial for the treatment of anti-GBM mediated glomerulonephritides."
04/15/2014 - "Galectin-9 ameliorates anti-GBM glomerulonephritis by inhibiting Th1 and Th17 immune responses in mice."
04/01/2009 - "In conclusion, blockade of JNK signaling provides substantial protection against the progression of crescentic anti-GBM glomerulonephritis, which may be, in part, due to inhibition of the macrophage proinflammatory response."
02/01/2003 - "Blockade of p38alpha MAPK ameliorates acute inflammatory renal injury in rat anti-GBM glomerulonephritis."
05/01/2013 - "In the present study, we sought to establish whether recombinant RPS19 can exert anti-inflammatory effects in a mouse model of anti-GBM (glomerular basement membrane) GN (glomerulonephritis) in which MIF is known to play an important role. "
|9.||Cyclosporine (Ciclosporin)FDA LinkGeneric
01/01/2001 - "There was a lower rate of remission and a high risk of cyclosporine nephrotoxicity in other types of glomerulonephritis. "
05/01/1986 - "Therefore, we feel that both cyclosporin and (Nva2)-cyclosporin may be useful in the treatment of human glomerulonephritis where there is an autoimmune component."
04/01/2014 - "Biopsy after 3 months showed normal histology 54.28%, clinical rejection 11.42%, sub clinical rejection 5.7%, borderline change 5.7%, cyclosporine toxicity 5.7% & 2.8% recurrent glomerulonephritis. "
01/01/2013 - "We investigated time-dependent expression of CXCR1 and the effect of single-dose cyclosporine A (CsA) treatment on this expression in experimental mesangioproliferative glomerulonephritis induced by anti-thymocyte serum (ATS). "
04/01/2009 - "Cyclosporin A using in treatment glomerulonephritis can cause neurological side effects. "
|10.||Idiopathic minimal change nephrotic syndromeIBA
06/01/2003 - "Nineteen refractory nephrotic patients with minimal change disease or mesangial proliferative glomerulonephritis were enrolled in this study. "
11/01/2014 - "The most common causes of primary glomerulonephritis were Minimal Change Disease (MCD) (n=267, 21.8%), diffuse proliferative glomerulonephritis (n=188, 15. "
07/01/2013 - "Minimal change disease/mild disease (MCD/ML), IgAN and mesangial proliferative glomerulonephritis (MsPGN) were the most common pathological patterns of PGN. "
02/01/2013 - "Moreover, although there has been an unchanged total annual rate of biopsy-proven PGN (P = 0.47), there has been a significant enhancement in the incidence of minimal change disease (MCD, P = 0.04) and extracapillary proliferative glomerulonephritis (ExGN, P = 0.03) over time primarily due to a progressive increase in the mean age of patients affected by both renal diseases. "
06/01/2010 - "Overall, mesangial proliferative glomerulonephritis (MesGN) was the commonest histology (49/157, 31.2%), followed by minimal change disease (MCD) (36/157, 22.9%) and diffuse proliferative glomerulonephritis (DPGN) (26/157, 16.6%). "
01/01/2014 - "Starting plasma exchange improved her renal function and removed MPO-ANCAs, which were suspected to play the major role in the pathogenesis of glomerulonephritis. "
11/27/1981 - "The combination of plasma exchange and immunosuppression appears to result in considerable improvement of therapeutic measures in rapidly progressive glomerulonephritis. "
01/01/1988 - "Thus, in non-autoantibody induced rapidly progressive glomerulonephritis, kidney function could be improved substantially by immunosuppressive therapy, but an advantage of supplementary plasma exchange could not be shown."
07/01/1986 - "Efficacy of plasma exchange in severe idiopathic rapidly progressive glomerulonephritis. "
07/01/1983 - "Improved outcome in rapidly progressive glomerulonephritis by plasma exchange treatment."
05/01/1985 - "[Improvement in the prognosis of rapid progressive glomerulonephritis by plasmapheresis treatment]."
01/01/1994 - "Adjuvant plasmapheresis use in glomerulonephritis treatment needs further studies."
01/01/1991 - "A study was made of the effect produced by a short-term course of plasmapheresis (PA) combined with cytostatic, glucocorticoid and deaggregation therapy on the clinico-laboratory characteristics in 45 patients suffering from chronic glomerulonephritis (CGN). "
01/01/1977 - "Drainage of the thoracic duct and plasmapheresis may be of benefit in the treatment of glomerulonephritis, but their proper utilization requires further studies."
07/01/2008 - "On 12th day of admission rapidly progressive glomerulonephritis was diagnosed and she received plasmapheresis and haemodialysis support. "
11/01/1981 - "Twenty-one of the 29 patients with severe proliferative glomerulonephritis had sustained improvement in renal function after treatment. "
03/31/1937 - "Histological study of those animals which die from 3 to 11 months after treatment reveals a chronic progressive glomerulonephritis with generalized vascular lesions."
01/01/2011 - "Among glomerular macrophages, the CD163(+) subset was significantly increased after treatment, suggesting that Treg cells may modulate the phenotype of macrophages leading to resolution of glomerulonephritis. "
01/01/1978 - "It is reported on 37 patients in whom on the basis of the clinical suspicion of a glomerulonephritis a biopsy of the kidneys was carried out, and after treatment in these patients a rebiopsy was carried out 21 months later in order to examine clinical and histological changes during this period. "
12/30/1975 - "Results of three months' treatment of 10 glomerulonephritic, 10 normal guinea pigs and of 10 normal rats with imurek (20 mg/kg/day) were as follows: 1. The morphological picture of glomerulonephritis was demonstrable even three months after treatment with imurek. "
01/01/2008 - "The aim of this study was to evaluate efficacy of therapeutic interventions undertaken in post-transplant glomerulonephritis. "
01/01/2009 - "Five months after the withdrawal of EV, a third graft biopsy showed remission of the necrotizing glomerulonephritis. "
04/01/2012 - "We performed a retrospective, single-center study to evaluate the effect of recurrent glomerulonephritis (GN) and ARE on outcomes of grafts with zero HLA-mismatches (n = 122) versus three to four mismatches (n = 317), and five to six mismatches (n = 102). "
06/15/2009 - "A 6-month observational study was conducted in a total of 51 patients, 35 with glomerulonephritis and 16 with kidney transplants. "
01/01/2004 - "As grafts last longer and recurrent glomerulonephritis becomes a more significant entity, affecting greater numbers of patients, the opportunity to study management prospectively will be possible. "
11/01/2015 - "Likely Recurrence of C3 Glomerulonephritis in Kidney Transplantation: An Entity to Bear in Mind: Case Report."
10/01/2015 - "Recurrent Glomerulonephritis in Renal Transplantation: Experience in Our Renal Transplantation Center."
03/01/2015 - "It is important to state that glomerulonephritis as the primary renal disorder does not represent a contraindication for kidney transplantation, including living kidney donation. "
11/01/2013 - "Statin use after renal transplantation improves long-term outcome and reduces the incidence of glomerulonephritis. "
10/01/2013 - "Recurrence of glomerulonephritis after renal transplantation."